News
Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed ...
It's difficult to get motivated about buying a stock that's plummeted or a company that seems to be out of favor with the ...
Biotech stumbled in FY25, but we didn’t. HB Biotechnology kept its footing and delivered 23% outperformance in a tough market ...
In July 2025, global markets have been navigating a complex landscape marked by new U.S. tariff announcements and mixed economic signals, with the Nasdaq Composite Index showing resilience amidst ...
StockStory.org on MSN3d
Why Moderna (MRNA) Stock Is Falling TodayShares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its ...
2d
MarketBeat on MSNGoldman Spotlights These 3 Stocks in Its Bullish S&P 500 OutlookDetailed price information for Verve Therapeutics Inc (VERV-Q) from The Globe and Mail including charting and trades.
My all-weather portfolio gained 23% in H1, driven by tech, energy, and real assets amid rate cut hopes. See why I'm targeting ...
Simulations Plus Inc. reported lower than expected sales and reduced guidance due to cautious biopharma spending.
These ASX 100 shares could rise in July after a very different past year. Here's what to consider about the two.
Health care stocks have outperformed so far in 2025 despite uncertainty surrounding the Donald Trump administration's policies. Health care stocks can often be a solid defensive play in an ...
Thermo Fisher's core pharma, biotech, and bioproduction businesses are driving growth. Click here to read why TMO stock is a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results